

Full Portfolio Holdings* as of February 28, 2026

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
BASE CURRENCY					
US DOLLAR			919,263	919,263	0.81%
COMMON STOCKS					
Eli Lilly & Co.			13,326	14,018,819	12.41%
Merck & Co., Inc.			58,295	7,218,087	6.39%
Johnson & Johnson			24,644	6,122,309	5.42%
UnitedHealth Group, Inc.			16,106	4,723,407	4.18%
AbbVie, Inc.			18,015	4,180,921	3.70%
Intuitive Surgical, Inc.			8,008	4,032,108	3.57%
Abbott Laboratories			30,118	3,504,229	3.10%
Edwards Lifesciences Corp.			40,235	3,479,120	3.08%
Danaher Corp.			15,625	3,291,250	2.91%
Vertex Pharmaceuticals, Inc.			5,853	2,907,946	2.57%
Cencora, Inc.			6,821	2,538,367	2.25%
Boston Scientific Corp.			28,216	2,168,400	1.92%
HCA Healthcare, Inc.			3,635	1,925,460	1.70%
Thermo Fisher Scientific, Inc.			3,624	1,888,503	1.67%
CVS Health Corp.			23,150	1,849,685	1.64%
Elevance Health, Inc.			5,698	1,823,360	1.61%
Medtronic PLC			18,617	1,818,136	1.61%
UCB SA			5,633	1,692,060	1.50%
Cardinal Health, Inc.			7,360	1,687,133	1.49%
Regeneron Pharmaceuticals, Inc.			2,157	1,686,062	1.49%
GSK PLC			49,604	1,473,898	1.31%
Agilent Technologies, Inc.			11,491	1,394,778	1.23%
Stryker Corp.			3,578	1,386,332	1.23%
Dexcom, Inc.			16,874	1,239,058	1.10%
United Therapeutics Corp.			2,368	1,193,235	1.06%
AstraZeneca PLC			5,535	1,153,771	1.02%
Biogen, Inc.			5,926	1,136,725	1.01%
STERIS PLC			4,043	1,020,251	0.90%
Argenx SE			1,306	1,001,598	0.89%
Ionis Pharmaceuticals, Inc.			11,237	911,883	0.81%
Galderma Group AG			4,581	864,480	0.77%
Elanco Animal Health, Inc.			31,004	818,506	0.72%
Ascendis Pharma AS			3,460	807,910	0.72%
Bristol-Myers Squibb Co.			12,812	799,084	0.71%
Incyte Corp.			7,538	763,373	0.68%
Encompass Health Corp.			6,943	749,011	0.66%
Kymera Therapeutics, Inc.			7,910	722,579	0.64%
Revolution Medicines, Inc.			6,612	674,556	0.60%
Madrigal Pharmaceuticals, Inc.			1,536	663,552	0.59%
Option Care Health, Inc.			20,393	661,957	0.59%

Full Portfolio Holdings* as of February 28, 2026

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Alnylam Pharmaceuticals, Inc.			1,953	650,193	0.58%
Disc Medicine, Inc.			9,537	635,355	0.56%
Protagonist Therapeutics, Inc.			6,877	633,234	0.56%
Cytokinetics, Inc.			9,927	617,658	0.55%
Alignment Healthcare, Inc.			31,513	605,680	0.54%
Arcus Biosciences, Inc.			29,575	602,443	0.53%
Pharvaris NV			21,196	601,754	0.53%
Avantor, Inc.			66,012	597,409	0.53%
Vaxcyte, Inc.			9,593	592,272	0.52%
Qiagen NV			11,870	591,126	0.52%
Bio-Techne Corp.			9,988	589,292	0.52%
ICON PLC			5,368	580,496	0.51%
HeartFlow, Inc.			24,312	563,066	0.50%
Acadia Healthcare Co., Inc.			22,809	534,643	0.47%
Xenon Pharmaceuticals, Inc.			11,984	518,068	0.46%
Oculis Holding AG			17,442	512,969	0.45%
PTC Therapeutics, Inc.			7,369	502,492	0.44%
Viridian Therapeutics, Inc.			16,993	499,254	0.44%
Mirum Pharmaceuticals, Inc.			5,399	498,274	0.44%
Natera, Inc.			2,394	498,048	0.44%
Celldex Therapeutics, Inc.			16,231	488,391	0.43%
Dianthus Therapeutics, Inc.			8,761	483,520	0.43%
Apogee Therapeutics, Inc.			6,845	479,150	0.42%
Structure Therapeutics, Inc.			7,466	470,209	0.42%
Soleno Therapeutics, Inc.			11,658	455,478	0.40%
Apellis Pharmaceuticals, Inc.			20,657	432,971	0.38%
Inspire Medical Systems, Inc.			6,596	425,508	0.38%
Mineralys Therapeutics, Inc.			14,421	421,958	0.37%
Nuvalent, Inc.			4,103	418,301	0.37%
Immunocore Holdings PLC			12,125	391,638	0.35%
Jiangsu Hengrui Pharmaceuticals Co. Ltd.			45,725	388,505	0.34%
Immunome, Inc.			16,589	362,636	0.32%
Scholar Rock Holding Corp.			7,975	353,053	0.31%
Trevi Therapeutics, Inc.			28,925	344,786	0.31%
Crinetics Pharmaceuticals, Inc.			8,142	334,636	0.30%
Newamsterdam Pharma Co. NV			9,285	329,246	0.29%
Aktis Oncology, Inc.			16,033	322,744	0.29%
GenFleet Therapeutics Shanghai, Inc.			91,400	320,111	0.28%
Adaptive Biotechnologies Corp.			14,523	232,658	0.21%
VeraDermics, Inc.			3,300	151,305	0.13%
CG oncology, Inc.			1,875	110,250	0.10%
Corvus Pharmaceuticals, Inc.			4,000	73,040	0.06%
Eikon Therapeutics, Inc.			4,200	57,876	0.05%
FOREIGN CURRENCY					
BRAZILIAN REAL			226,512	44,185	0.04%
SWISS FRANC			35	45	0.00%

Full Portfolio Holdings* as of February 28, 2026

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
EURO CURRENCY			19	22	0.00%
DANISH KRONE			34	5	0.00%
HONG KONG DOLLAR			5	0.58	0.00%
JAPANESE YEN			1	0.01	0.00%
POUND STERLING			(0.16)	(0.22)	0.00%
RIGHTS					
Abiomed, Inc.		12/31/2099	885	903	0.00%
SHORT-TERM INVESTMENTS					
Fixed Income Clearing Corp.		3/2/2026	231,468	231,468	0.20%
DERIVATIVES - FOREIGN CURRENCY EXCHANGE CONTRACTS (SPOT)					
POUND STERLING		3/3/2026	(82,867)	(119)	0.00%
TOTAL INVESTMENTS				112,459,363	99.57%
OTHER ASSETS LESS LIABILITIES				480,244	0.43%
TOTAL NET ASSETS				112,939,607	100.00%

* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on www.hartfordfunds.com for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual Financial Statements and Other Information filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT. In addition, the number of portfolio holdings listed above, which is sourced from the Fund's custodian, may differ from the "number of holdings" and related data points in the Fund Stats section of the webpage which is sourced from the sub-adviser.

Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

4673945 07/25